Candel Therapeutics Inc. Extends Lease Agreement for Needham Premises Until 2029

Reuters
Aug 22
Candel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Extends Lease Agreement for Needham Premises Until 2029

Candel Therapeutics Inc. has confirmed the extension of its lease agreement with 117 Kendrick DE, LLC for its premises at 117 Kendrick Street, Needham, Massachusetts. The original lease, dated February 4, 2019, has been amended to extend the term from August 31, 2026, to August 31, 2029. Starting September 1, 2026, the base rent for the approximately 15,197 rentable square feet will be set at $607,880 per year, with annual increases of $15,197 during the extended term. This agreement is documented in a First Amendment to Lease Agreement, filed as Exhibit 10.1 in the company's latest Form 8-K report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-110682), on August 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10